Lupin recalls two lots of antibiotic drug 'Suprax' in US market

Tags: Companies
Drug major Lupin is voluntarily recalling 9,210 bottles of its antibiotic drug Suprax, used to treat bacterial infections, in the US market, according to the US Food and Drug Administration (USFDA).

As per the information available on the USFDA website, Lupin Pharmaceuticals Inc, the US-based unit of the company, is recalling two lots of Suprax as the "product did not meet specification in total impurities at the nine-month stability station".

The company is recalling 4,038 bottles of Suprax in the first lot and 5,172 bottles of the drug in the second lot in the US market, it added.

The nationwide recall has been initiated by the company on January 27 this year.

The recall of the drugs has been initiated under Class-III which FDA defined as "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences".

When contacted, a Lupin spokesperson said: "This is a voluntary recall initiated on our own and of no business consequence."

Last year also, the Mumbai-based firm had voluntarily recalled 64,368 bottles of Suprax in the US market on account of discolouration.

Suprax contains cefixime, which is a third-generation oral cephalosporin that has an important role in treating common infections.

EDITORIAL OF THE DAY

  • Government must consider Sitharaman’s move to revisit Apple’s application for retail

    Commerce and industry minister Nirmala Sitharaman’s decision to revisit the Apple application for waiver of mandatory local sourcing, if taken serio

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Arun Nigavekar

Can Hefa actually become a reality?

The ministry of human resource development (MHRD) is actively wo­rking ...

Zehra Naqvi

Man proved to be a tyrant and a fool

Reading the history of different species is, perhaps, the most ...

Dharmendra Khandal

No one's getting rich overnight by poaching

We often read in newspapers that tiger skin worth Rs ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture